CMS issues favorable decision on prostate Ca immunotherapy coverage

April 14, 2011

The advanced prostate cancer autologous cellular immunotherapy sipuleucel-T (Provenge) improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer and thus is reasonable and necessary for that indication, according to a proposed decision memo from the Centers for Medicare & Medicaid Services.

The advanced prostate cancer autologous cellular immunotherapy sipuleucel-T (Provenge) improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer and thus is reasonable and necessary for that indication, according to a proposed decision memo from the Centers for Medicare & Medicaid Services.

According to Dendreon Corp., the maker of sipuleucel-T, Medicare beneficiaries currently are able to access sipuleucel-T, as Medicare Administrative Contractors covering all 15 regional territories have established coverage guidelines and/or provided physicians with written or verbal guidance on coverage. The American Medical Association said that, if finalized, the national coverage determination would apply the same coverage standard to all beneficiaries.

Related Content:

Drug Therapy